Report Date: Thursday, August 6, 2026 (before market open) | Call: 11:00 a.m. ET
Parker Hannifin heads into its fiscal Q4/full-year FY26 report near multi-month highs, trading around $990-$997, just off 52-week highs after a run that has seen the stock find support near the $930 level in early July before recovering toward the $985–$990 range by late July, following a rally that gained more than 36% over the past 12 months. Sentiment is broadly bullish — consensus rating is "Buy" based on insights from 25 analysts, with 21 recommending buy, 1 sell, and 5 hold — though the stock trades at 21.3x F2027E EBITDA and 29.0x F2027E EPS, above its 5-year averages and at a premium to peers, leaving less room for error.
Importantly, Parker has a strong recent beat history — last quarter EPS of $8.17 surpassed the analyst forecast of $7.84, and revenue exceeded expectations at $5.49 billion versus $5.4 billion anticipated — but Street models haven't always been conservative: Parker-Hannifin has missed Wall Street's revenue estimates multiple times over the last two years, a useful reminder that this isn't an automatic beat-and-raise setup.
Consensus expectations: Wall Street analysts expect Parker-Hannifin to post quarterly earnings of $8.30 per share, a year-over-year increase of 7.9%, on revenues of $5.61 billion, up 6.9% from the year-ago quarter.
Company's own Q4 guide (given with Q3 results in April): management guided reported sales to be nearly $5.5 billion, a 5.5% increase versus prior year, with organic growth of approximately 4%, adjusted segment operating margins of 27.4%, an effective tax rate of 22%, and adjusted EPS of $8.16. Notably, the Street's $8.30/$5.61B is running slightly ahead of the company's own internal Q4 guide — consistent with Parker's pattern of guiding conservatively and beating.
Full-year FY26 targets to reconcile against: the last update called for reported sales growth of 7%, organic sales growth of 5.5%, segment operating margin of 23.9% (27.2% adjusted), and EPS of $27.10 reported ($31.20 adjusted).
Parker's fiscal Q3 (reported April 30) was a record quarter across the board: sales increased 11% to a record $5.5 billion, with organic sales up 6.5%, segment operating margin of 23.4% (26.7% adjusted), adjusted EPS up 18% to a record $8.17, and orders up 9%. Cash generation was equally strong, with year-to-date cash flow from operations at a record $2.6 billion, or 16.7% of sales. Segment detail showed Aerospace as the standout — sales up 15.5% (14.2% organic) on 22% commercial OEM growth and 14% aftermarket growth, with adjusted margin of 29.5% — while Industrial showed a broadening but still-gradual recovery, with North America organic growth of 2.8% and International organic growth of 3.3%, led by 9.6% organic growth in Asia. Backlog rose to a record $12.5 billion, providing good visibility into Q4 and FY27.
On the call, CFO Todd Leombruno raised Q4 Aerospace organic growth guidance to roughly 9% (from 7.5% previously) and management reiterated no signs of demand deceleration, with orders described as "strong throughout the quarter" and industrial order momentum broadening across both short- and long-cycle businesses.
1. Aerospace momentum — can the streak continue? Aerospace is Parker's largest and most profitable vertical. Management guided Q4 organic growth of ~9%, which would mark a fourth consecutive year of double-digit organic growth for the segment on a full-year basis, backed by record backlog and continued commercial OE/aftermarket strength. Watch for commentary on OEM production rates, defense demand given ongoing geopolitical tension, and whether margin expansion (29.5% adjusted in Q3) can be sustained as OEM mix (which runs at lower margin than aftermarket) increases.
2. Industrial recovery — durability and mix Industrial order growth has now been positive for multiple quarters running, and management raised full-year International organic guidance to 2.5%. Investors will want confirmation that North America and International industrial trends held up in Q4, that distributor inventories remain in a "order-to-demand" posture rather than restocking, and early color on whether FY27 industrial growth can step up from FY26's roughly 2.5% pace — a question analysts pushed on directly during the Q3 call without getting a firm answer.
3. Two transformative, pending acquisitions — integration and financing Parker is mid-stream on two sizable deals that will dominate the forward narrative: - Filtration Group Corporation ($9.25 billion cash deal announced November 2025), a global provider of filtration technologies across life sciences, HVAC/refrigeration, and in-plant/industrial verticals, expected to close within 12 months of the announcement, i.e., by fiscal 2027. - CIRCOR's Commercial and Defense Aerospace business ($2.55 billion cash deal announced May 21, 2026), a cash-free, debt-free acquisition expected to generate calendar 2026 sales of approximately $270 million with adjusted EBITDA margins of more than 40% before synergies, expected to close in the second half of calendar 2026.
Investors should listen for updated closing timelines, regulatory progress, financing plans, and early integration commentary — plus how these deals feed into an initial FY27 outlook.
4. Balance sheet and credit trajectory S&P Global Ratings revised its outlook on Parker-Hannifin to positive from stable, affirming its 'BBB+' issuer credit rating, citing strong operating performance and adjusted leverage declining to 1.6x as of March 31, 2026. The positive outlook reflects potential for a rating upgrade if Parker successfully integrates the Filtration Group acquisition and maintains leverage below 3x over the next 18-24 months, with S&P forecasting adjusted leverage of 2.7x by the end of fiscal 2027 post-close, before Parker delevers back toward its roughly 2x target. Expect questions on capital allocation sequencing — buybacks, the dividend (raised 11% last quarter, extending Parker's dividend-increase streak to 70 consecutive fiscal years), and further M&A appetite once Filtration Group and CIRCOR close.
5. Tariffs, price/cost, and macro Management has consistently said price/cost management is a "core element" of its Win Strategy and that tariff dynamics have not impacted earnings. Watch for any updated commentary given evolving trade policy, plus segment-level detail on price realization versus input cost inflation.
6. Initial FY27 framework Historically Parker gives a first look at next-year guidance with the Q4/full-year release. Given record backlog in both segments, analysts (e.g., Bernstein) have flagged potential upside to the Diversified Industrial segment's conservative 2.5% growth assumption. The tone and specifics of the FY27 outlook — particularly how much of Filtration Group and CIRCOR Aerospace get baked in — will likely be the single biggest swing factor for the stock reaction.
Parker enters this print with strong operating momentum (record sales, margins, cash flow, and backlog in Q3), a credit story trending positively, and a premium valuation that already prices in continued execution. The Street's Q4 estimates sit slightly above management's own guidance, which is consistent with Parker's recent beat-and-raise pattern but leaves a real bar to clear. Beyond the headline Q4 print, the more market-moving elements are likely to be: (1) the initial FY27 guide, (2) updated timing/financing detail on the Filtration Group and CIRCOR Aerospace deals, and (3) confirmation that the industrial recovery is broadening rather than plateauing.